Alfuzosin Hydrochloride Tablet, Extended Release
Product Images NDC 47335-956

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Alfuzosin Hydrochloride (NDC 47335-956). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sun Pharmaceutical Industries, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Chemical-structure (Chemical Structure)

Chemical-structure (Chemical Structure)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
The text describes a graph with the mean change in IPSS Total Symptom Score over 28 and 56 days of treatment, comparing a placebo treatment (N=152) with Alfuzosin hydrochloride extended-release tablets (N=137). The graph shows a statistically significant difference (p < 0.01) between the two treatments.*
FDA Label Image

Figure-4 (Figure 4)

Figure-4 (Figure 4)
The text provides a graph showing the mean change from baseline in IPSS Total Symptom Score for a trial of a placebo group (N=150) compared to a group taking Aituzosin hydrochloride extended-release tablets (N=151) over 28 and 56 days of treatment. The graph shows a statistically significant difference at p<0.01.*
FDA Label Image

Figure-5 (Figure 5)

Figure-5 (Figure 5)
This is a graph showing the mean change from baseline in peak urine flow rate (mL/s) over 56 days of treatment with a placebo and Alfuzosin hydrochloride extended-release tablets in two separate groups of 167 and 170 individuals respectively. The graph indicates a significant improvement in mean urine flow rate with the use of the medication compared to placebo.*
FDA Label Image

Figure-6 (Figure 6)

Figure-6 (Figure 6)
The text is a figure titled "Mean Change from Baseline in Peak Urine Flow Rate (mL/s): Trial 2". It appears to be a comparison between a Placebo group (with N=147) and a group treated with Atuzosin hydrochloride extended-release tablets (with N=136). The figure shows the days of treatment and the peak urine flow rate expressed in mL/s, and indicates that there is a statistically significant difference between the two groups, where the Atuzosin group showed a higher peak urine flow rate than the Placebo group.*
FDA Label Image

Figure-7 (Figure 7)

Figure-7 (Figure 7)
The text is describing a figure that shows the mean change from baseline in peak urine flow rate in Trial 3. The figure compares the results of placebo (N=150) to Alfuzosin hydrochloride extended-release tablets (N=151) over a treatment period of 84 days. The statistical analysis shows no significant difference between the two groups (NS p > 0.05).*
FDA Label Image

Label (Label)

Label (Label)
Alfuzosin Hydrochloride Extended-Release Tablets are medicine tables containing USP 10 mg of alfuzosin hydrochloride used for medication purposes. The usual dosage information is available in the package insert. It needs to be stored in a tightly closed, light-resistant container protected from light and moisture at a temperature between 20°C and 25°C (68°F to 77°F); excursions are permitted between 15°C and 30°C (59°F and 86°F) as per USP Controlled Room Temperature. Patient Information is available at ps:fwerw.sunpharma.com/usa/products. It should be kept out of children's reach. NDC (National Drug Code) for Alfuzosin Hydrochloride Extended-Release Tablets is 47335-95681, consisting of 90 Tablets. A pharmacist must dispense the tablets with the patient information. The text further contains information on distribution, manufacturing, and a unique identifier code.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.